1. Home
  2. Investing
  3. Stocks
  4. USA
  6. CorMedix Inc (CRMD)
  7. Quote


CorMedix Stock Price

-0.18 (-3.68%)
Volume 194,685
Bid Price 4.71
Ask Price 4.78
News -
Day High 4.89


52 Week Range


Day Low 4.625
Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
CorMedix Inc CRMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.18 -3.68% 4.71 16:22:30
Open Price Low Price High Price Close Price Prev Close
4.89 4.625 4.89 4.76 4.89
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,278 194,685 $ 4.74 $ 923,271 - 4.36 - 18.80
Last Trade Time Type Quantity Stock Price Currency
16:24:21 25 $ 4.71 USD


Draw Mode:

CorMedix Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 179.39M 38.09M 37.61M $ 239.23k $ - -0.76 -6.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 10.00%

more financials information »

CorMedix News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRMD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.065.064.6254.85144,799-0.35-6.92%
1 Month4.695.084.524.79161,8090.020.43%
3 Months5.916.754.365.25229,077-1.20-20.3%
6 Months7.958.944.366.50289,646-3.24-40.75%
1 Year9.7618.804.369.83631,016-5.05-51.74%
3 Years9.7618.804.369.83631,016-5.05-51.74%
5 Years9.7618.804.369.83631,016-5.05-51.74%

CorMedix Description

Cormedix Inc is a biopharmaceutical company which focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. The Neutrolin product is designed to target unmet medical need.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.